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Introduction. Human papillomavirus (HPV) is responsible for almost all cervical cancers, for an important fraction of 
other anogenital cancers (anus, vulva, vagina and penis), but also for some head and neck cancer cases. 
Material and method. Data on cancer incidence for Poland in 2015 were taken from the database of Polish National 
Cancer Registry (http://onkologia.org.pl). Attributable fractions (AFs) for all HPV-associated cancer sites were derived 
from published study. The number of cancer cases attributable to HPV infections was calculated by multiplying the 
number of registered new cancer cases by the given AF for all HPV-associated cancer sites. 
Results. Of all newly registered cancer cases for Poland in the analysed year, 4080 were estimated to be attributable to 
HPV infections. The vast majority of these cases — 3300, were diagnosed in women, 780 in men. Cancer cases attributed 
to HPV represent 44% of all cancers related to HPV and 2.5% of all malignant neoplasms registered in Poland in 2015. 
Conclusions. The fraction of cancers attributable to HPV infections is highly dominated by cervical cancer. Effective 
control of this cancer site should combine increasing awareness of threats related to HPV infections, improving access 
to HPV vaccination (primary prevention) by introduction of financing from public funds, and increasing access to 
secondary prevention in both forms — cytological and HPV testing. Introduction of an HPV vaccination population 
program in Poland should be a priority in strategy of cancer control.
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Introduction
Human papillomavirus (HPV) is responsible for almost 
all cervical cancers, for an important fraction of other ano-
genital cancers (anus, vulva, vagina and penis), but also for 
some head and neck cancer cases. In 2012 4.5% of all cancers 
worldwide were attributed to HPV (8.6% in women and 0.8% 
in men) [1]. These cancers can be effectively eliminated by 
known primary and secondary prevention methods. 
Objective
The aim of this publication is to estimate the number 
of cancer cases attributed to HPV infections for Poland in 
2015. It also draws attention to the fact that it is a significant 
public health problem.
Material and method
Data on cancer incidence for Poland in 2015 were ta-
ken from the database of Polish National Cancer Registry 
(http://onkologia.org.pl). Attributable fractions (AFs) for all 
HPV-associated cancer sites (cervix uteri, other anogenital 
sites: anus, vulva, vagina, penis, and head and neck cancer: 
oropharynx, oral cavity and larynx) were derived from a stu-
dy published in 2016, prepared by M. Plummer and others 
[2]. For vulvar cancer we used AFs specific for the age. For 
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oropharyngeal cancer, AF calculated for East Europe was 
taken for analyses.
The number of cancer cases attributable to HPV infec-
tions was calculated by multiplying the number of registered 
new cancer cases by the given AF for all HPV-associated 
cancer sites. 
Results
In 2015 over 160 000 new malignant neoplasms cases 
were noted in Poland (according to International Classifi-
cation of Diseases, 10th Revision (ICD-10) codes: C00-C97) 
of which 80 867 among men and 79 230 among women. 
HPV-associated cancer sites constituted 4473 and 4761 cases 
respectively. 
Of all newly registered cancer cases for Poland in the 
analysed year, 4080 were estimated to be attributable to 
HPV infections (Tab. I). The vast majority of these cases — 
3300, were diagnosed in women, 780 in men. Cancer cases 
attributed to HPV represent 44% of all cancers related to 
HPV and 2.5% of all malignant neoplasms registered in 
Poland in 2015.
For women, the large majority of total number of can-
cer attributable to HPV was contributed by cervical cancer 
(2723), followed by anus (201), oropharynx (140), vulva (119), 
vagina (81), oral cavity (21) and larynx cancer (16). These 
cancer cases together constitute 69% of the total number 
of cancer associated with HPV and 4.2% off all registered 
cancer cases for women.
Among men, the biggest contribution was for oropha-
rynx (418), smaller for penis (124), larynx (100), anus (90) and 
oral cavity (48). Cases attributable to HPV constitute 17% of 
cancer related to HPV and 1.0% of all cancers occurring in 
Poland in 2015 for men.
Discussion and conclusions
The obtained results for Poland for 2015 are similar to 
the results for the whole Europe presented in the paper pre-
pared by de Martel C et al. [1], where also 2.5% of all cancer 
were attributed to HPV, 4.4% in women and 0.9% in men.
The fraction of cancers attributable to HPV infections 
is highly dominated by cervical cancer, which constituted 
2/3 of the total number of cancers attributable to HPV in 
Poland in 2015 and 83% of all cancers attributable to HPV 
for women. 
Cervical cancer is one of the most preventable can-
cers. Effective control of this cancer site should combine 
increasing awareness of threats related to HPV infection, 
improving access to HPV vaccination (primary prevention) 
by introduction of financing from public funds, and incre-
asing access to secondary prevention in the form of HPV 
testing and cytological tests. These may lead in the future 
to the significant morbidity and mortality reduction of HPV-
-associated cancer in Poland. The Nordic countries’ example 
proves that effective implementation of preventive health 
strategies leads to excellent results. In these countries cervi-
Table I. Number of HPV-associated and HPV-attributable cancer cases in Poland in 2015
Cancer site (ICD-10 code) Sex Number of HPV-associated 
cancer cases
AF Number of HPV-attributable 
cancer cases
Cervix
(C53)
Female 2723 100% 2723
Vulva
(C51)
Female 581 Age 15–54 years: 48%
Age 55–64 years: 28%
Age 65+ years: 15%
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Vagina
(C52)
Female 104 78% 81
Penis
(C60)
Male 243 51% 124
Anus
(C21)
Female 228 88% 201
Male 102 90
Oropharynx
(C01, C09-C10)
Female 279 50% 140
Male 836 418
Oral cavity
(C02-C06)
Female 491 4.3% 21
Male 1121 48
Larynx
(C32)
Female 355 4.6% 16
Male 2171 100
TOTAL Both sexes 9234 44% 4080
Female 4761 69% 3300
Male 4473 17% 780
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cal cancer mortality has decreased for many years and now 
it is a marginal problem [3].
Although vaccination against HPV is considered to be 
the most effective strategy to reduce mortality from cervical 
cancer and other cancers associated with HPV infections [1], 
Pap test is still the basic method of prophylaxis in Poland. 
Introduction of a population program of HPV vaccination 
in Poland should be a priority in strategy of cancer control.
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